文献速递前列腺癌

高强度聚焦超声部分腺体消融治疗局限性前列腺癌的肿瘤学与功能学结局

Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.
PubMed 文献 · J Urol · 2019-01-01

该回顾性多中心分析纳入2013年1月至2017年9月接受Sonablate® 500系统部分腺体消融的150例局限性前列腺癌患者,共166次手术,89%为Grade Group≥2。中位随访24.3个月,PSA平均下降65%,高风险患者确认活检中42%检出临床显著癌,24.6%接受挽救治疗,81%患者避免全腺体治疗。

要点

  • HIFU部分腺体消融对功能影响小,严重并发症罕见
  • 高风险患者局部复发或失败率达42%
  • 肿瘤位于内侧与更高复发风险相关

核心结论

  • HIFU部分腺体消融治疗局限性前列腺癌安全且对功能影响小,但高风险患者局部复发或失败率为42%。

研究设计与样本

  • 回顾性多中心分析纳入2013年1月至2017年9月接受Sonablate® 500系统部分腺体消融的150例活检证实局限性前列腺癌患者,共166次手术,89%为Grade Group≥2。

主要发现

  • 平均随访24.3±14.4个月,PSA从7.9±6.8 ng/ml降至最低点2.7±3.1 ng/ml,平均下降65%。
  • 87例(52%)高风险患者接受确认活检,37例(42%)检出Grade Group≥2临床显著癌。
  • 37例(24.6%)接受挽救治疗,其中16例重复部分腺体消融。
  • 阳性穿刺针数更多、肿瘤位于内侧或PSA更高者复发概率更高。
  • 81%患者避免了全腺体治疗,严重并发症罕见。

临床怎么用

  • 对于偏好微创门诊治疗的局限性且MRI显示多灶性有限的前列腺癌患者,可考虑HIFU部分腺体消融以保留功能并避免全腺体治疗。
  • 术后应对高风险患者进行确认活检监测,内侧肿瘤患者需警惕更高失败率。

局限性

  • 回顾性研究设计。
  • 平均随访仅24.3个月。
  • 确认活检仅在52%高风险患者中进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the outcomes of high intensity focused ultrasound as primary treatment of localized prostate cancer in a retrospective series. This represents one of the largest published series of patients at intermediate and high risk. MATERIALS AND METHODS: We performed a retrospective multicenter analysis of patients who underwent partial gland ablation between January 2013 and September 2017. Patients with biopsy proven localized disease and limited multifocality based on magnetic resonance imaging who preferred minimally invasive outpatient therapy were treated with the Sonablate® 500 system. Oncologic and functional outcomes were analyzed as well as risk factors for recurrence. RESULTS: A total of 166 procedures were performed in 150 patients. Grade Group 2 or greater was present in 89% of cases. Mean ± SD followup was 24.3 ± 14.4 months. Mean prostate specific antigen decreased 65% from 7.9 ± 6.8 ng/ml to a nadir of 2.7 ± 3.1 ng/ml. Confirmatory biopsies were performed in 87 patients (52%) at high risk for recurrence. Clinically significant cancer (Grade Group 2 or greater) was detected in 37 cases (42%). Patients with a higher number of positive cores, a medial tumor location or higher prostate specific antigen had a higher probability of recurrence. Salvage treatment was done in 37 patients (24.6%), including 16 repeat partial gland ablation procedures. CONCLUSIONS: Partial gland ablation with high intensity focused ultrasound therapy was safe and it had a minimal impact on functional outcomes. Local recurrence and/or failure occurred in 42% of patients at high risk for recurrence. Medially located tumors were associated with a higher failure rate. Serious complications were rare. Whole gland treatment was avoided in 81% of patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bass R, Fleshner N, Finelli A, et al. Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. J Urol. 2019. PMID: 30577402. doi:10.1016/j.juro.2018.07.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。